0 Items - $0.00
Categories
A to Z

Alternative structural projections:

8-pCPT-2'-O-Me-cGMP

8- (4- Chlorophenylthio)- 2'- O- methylguanosine- 3', 5'- cyclic monophosphate ( 8-pCPT-2'-O-Me-cGMP ), sodium salt
Epac-negative control
Cat. No.: C 048
    
CAS No.: [625112-42-7]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: C 048-05
Unit: 5 µmol / ~2.6 mg
$187.00
For other salt forms please inquire. The membrane-permeant 8-pCPT-2'-O-Me-cGMP neither activates protein kinase G nor Epac and can thus be used as a control. Characterized by high lipophilicity and membrane permeability, as well as increased PDE stability. Detailed technical information available.  Reference: Haag et al., Naunyn-Schmiedeberg´s Arch. Pharmacol., 378, 617 - 630 (2008).
Cat. No. C 048
Patent Information Protected by patent n° EP 02077219.0 and foreign equivalents, exclusively licensed to BIOLOG LSI for research purposes only
CAS number [625112-42-7]
Purity > 98% HPLC
Salt form Sodium
Storage temperature -20°C / -4°F
Molecular formula C₁₇H₁₆ClN₅O₇PS · Na
Molecular weight [g/mol] 523,8
Modifications 8-cGMP, 2'-cGMP
Lipophilicity 2.75
Absorption max [nm] 276
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] 21500
  • 1. Haag S., Warnken M., Juergens U. R.Racke K., Naunyn-Schmiedeberg's Arch. Pharmacol., 378, 617 - 630 (2008), "Role of Epac1 in Mediating Anti-proliferative Effects of Prostanoid EP2 Receptors and cAMP in Human Lung Fibroblasts"